Lysophosphatidic acid regulates macrophage polarization via LPAR1 by suppressing inflammatory responses and promoting M2-like characteristics
Clinical and Experimental Immunology · 2026
DOI: 10.1093/cei/uxaf083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2026. Verfasst von Wataru Nagata und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, National Defense Medical College, Tokorozawa, Saitama, Japan. Hauptthemen laut MEDLINE: Receptors, Lysophosphatidic Acid, Lysophospholipids, Macrophages, Inflammation. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Sciences to Toshiaki Ishizuka.
Abstract (Originalsprache)
Lysophosphatidic acid (LPA) is a crucial bioactive lipid mediator involved in various physiological processes; however, its role in macrophage polarization remains poorly understood; therefore, this study aimed to elucidate the modulatory effect of LPA on macrophage polarization, particularly its ability to shift M1 macrophages towards an M2-like phenotype, using murine macrophage RAW264.7 cells to confirm the expression of LPA receptor 1 (LPAR1) through immunofluorescence staining, which revealed that treatment of resting MO macrophages with LPA decreased inflammatory cytokines (IL-6, TNF-α) and increased TGF-β, with similar effects observed in LPS-stimulated cells and reversed by the LPAR1 inhibitor AM095, and immunostaining demonstrated a notable shift from an M1- to M2-like phenotype, as evidenced by an increase in the arginase-1/CD68 ratio; furthermore, LPA significantly decreased lactate production and increased ATP production in M1 macrophages, promoting a shift towards oxidative phosphorylation and suggesting metabolic reprogramming towards an M2-like phenotype, significantly influencing macrophage polarization and promoting a shift from a pro-inflammatory M1-like phenotype to an anti-inflammatory M2-like phenotype; these results suggest that treatment with LPA may help ameliorate diseases characterized by aberrant macrophage polarization, providing insights for the development of potential therapeutic strategies for inflammatory and autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, National Defense Medical College, Tokorozawa, Saitama, Japan.
ORCID-Profile: Wataru Nagata
Förderung
- Japan Society for the Promotion of Sciences to Toshiaki Ishizuka
Zitieren
APA
Nagata, W., Kodama, K., Nakagawa, K., & Ishizuka, T. (2026). Lysophosphatidic acid regulates macrophage polarization via LPAR1 by suppressing inflammatory responses and promoting M2-like characteristics. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxaf083
Vancouver
Nagata W, Kodama K, Nakagawa K, Ishizuka T. Lysophosphatidic acid regulates macrophage polarization via LPAR1 by suppressing inflammatory responses and promoting M2-like characteristics. Clinical and Experimental Immunology. 2026. doi:10.1093/cei/uxaf083
BibTeX
@article{Nagata2026,
author = {Nagata, Wataru and Kodama, Kayoko and Nakagawa, Keiichi and Ishizuka, Toshiaki},
title = {Lysophosphatidic acid regulates macrophage polarization via LPAR1 by suppressing inflammatory responses and promoting M2-like characteristics},
journal = {Clinical and Experimental Immunology},
year = {2026},
doi = {10.1093/cei/uxaf083}
}
EUVIMED